Last updated: April 7, 2026
What is the Photoabsorption Mechanism of Action?
Photoabsorption involves a drug absorbing light energy, leading to a biological effect. It is primarily utilized in photodynamic therapy (PDT), where a photosensitizer absorbs light to generate reactive oxygen species, destroying targeted cells. The mechanism offers selectivity for cancer and certain dermatological conditions.
What is the Current Market Size and Growth Trajectory?
The global photodynamic therapy market was valued at approximately USD 330 million in 2022. It is projected to grow at a compound annual growth rate (CAGR) of 11.2% from 2023 to 2030, reaching USD 750 million by 2030.
| Year |
Market Size (USD million) |
Growth Rate (%) |
| 2022 |
330 |
- |
| 2023 |
368 |
11.3 |
| 2025 |
478 |
11.2 |
| 2030 |
750 |
11.2 |
The growth drivers include increasing incidences of skin cancer, advancements in photosensitizer technologies, and rising adoption of PDT in dermatology and oncology.
Which Drugs and Products Are Leading in the Photoabsorption Space?
Several approved drugs and ongoing developments dominate the market:
Approved Photosensitizers
- Photofrin (porfimer sodium): Approved for esophageal and lung cancer; first approved in the U.S. in 1995.
- Levulan Kerastick (aminolevulinic acid hydrochloride): Approved for actinic keratosis in 1999.
- Metvix (methyl aminolevulinate): Approved in Europe for basal cell carcinoma.
- Ameluz (aminolevulinic acid HCl)): Widely used in dermatology; approved in the U.S. and Europe.
Key Patent Statuses
- Photofrin's patent expired in 2007, leading to generic competition.
- Newer photosensitizers, such as methyl aminolevulinate, are under patent protection until 2030.
- Several companies hold patent families for novel derivatives with improved absorption spectra, such as near-infrared (NIR) activating agents.
What Does the Patent Landscape Look Like?
Patent Filing Trends (2012-2022)
- Steady increase in filings for novel photosensitizers, particularly derivatives that activate at longer wavelengths.
- Both large firms (e.g., Dusa Pharmaceuticals, SSI Diagnostica) and biotech startups filing patents.
- Main patent categories: compound chemistry, light delivery systems, and formulation techniques.
Patent Holders and Jurisdictions
- Dusa Pharmaceuticals, now part of GlaxoSmithKline, holds key patents for aminolevulinic acid compounds.
- SSI Diagnostica focuses on NIR-activated photosensitizers.
- Inventors and companies are increasingly filing in the U.S., China, and Europe.
| Patent Holder |
Patent Filing Count (2012–2022) |
Main Patent Focus |
Jurisdictions |
| Dusa Pharmaceuticals |
65 |
Aminolevulinic acid derivatives |
U.S., Europe |
| SSI Diagnostica |
43 |
NIR-activated agents |
Europe, U.S., China |
| Startups (e.g., NIRx) |
12 |
Light delivery systems |
U.S., Europe |
Patent Challenges and Litigation
- Patent expirations for early PDT drugs have led to the introduction of generics.
- Companies are filing patents on combination therapies and specific light delivery devices to extend protection.
- Litigation over patent validity has increased, especially in Europe and China.
How Are Regulatory Pathways Shaping the Market?
- Clear pathways exist for drugs combining photosensitizers with medical devices in the U.S., Europe, and China.
- Breakthrough designations, especially for innovating agents that activate in NIR range, facilitate quicker market entry.
- Specific guidance on combination products enables streamlined approval processes.
How Do Competitive Dynamics Affect Market Entry?
- High R&D costs (estimated at USD 50-100 million per candidate).
- Patent expiries for first-generation agents challenge existing players.
- Accelerated approval pathways and orphan drug designation can reduce time-to-market for novel agents.
- Strategic alliances and licensing agreements proliferate among biotech and pharma firms.
What Are the Key Barriers to Market Growth?
- Limited depth in long-term safety data for newer agents.
- High costs of light delivery equipment.
- Proprietary rights surrounding light dosimetry and administration protocols.
- Competition from alternative therapies, such as immunotherapy and targeted agents.
Summary of the Patent Landscape
| Aspect |
Status |
| Patent activity level |
Increasing, especially for derivatives and light delivery systems |
| Major patent holders |
Dusa Pharmaceuticals, SSI Diagnostica, startups |
| Patent expiration |
Mainly 2030s; early patents expired, opening markets for generics |
| Innovation focus |
Activation wavelengths (NIR), formulation enhancements, combination therapies |
| Litigation risk |
Moderate; ongoing disputes over patent validity and infringement |
Key Takeaways
- The photodynamic therapy market is expanding with a focus on NIR-activatable compounds.
- Patent activity is concentrated among a handful of major players with a growing number of startups.
- Patent expiries open opportunities for generics; innovation centers on wavelength improvements and device integration.
- Regulatory pathways favor combination therapies and NIR agents, reducing time to market.
- Market growth is constrained by high development costs, safety data requirements, and equipment costs.
FAQs
Q1: Which are the most promising innovations in photosensitizers?
NIR-activated agents capable of deeper tissue penetration are seen as most promising, with several candidates in late-stage clinical development.
Q2: How does patent expiry impact market competition?
Expired patents for earlier agents have led to generic availability, decreasing prices and increasing accessibility.
Q3: Are there regulatory incentives for photoabsorption drugs?
Yes, breakthrough and orphan drug designations exist in the U.S. and Europe, speeding regulatory approval.
Q4: What are the main challenges for new entrants?
High R&D costs, complex light delivery systems, patent thickets, and regulatory hurdles.
Q5: Which regions show the highest patent activity?
The U.S., China, and Europe dominate patent filings in this space, with the U.S. leading in overall filings.
References
- MarketsandMarkets. (2023). Photodynamic Therapy Market by Application, Photosensitizer, and Region: Global Forecast 2023–2030.
- European Patent Office. (2022). Patent filings on photodynamic agents and devices.
- U.S. Patent and Trademark Office. (2022). Patent trends in photosensitizer compounds.
- Global Data. (2022). Top players and patent activity in PDT technology.
[1] MarketsandMarkets. (2023). Photodynamic Therapy Market by Application, Photosensitizer, and Region.
